"There are enough reports of it, enough interest in it, that we actually did -- ivermectin, in particular -- engage in sort of a better preclinical study of its properties and its ability to kill cancer cells," said Anthony Letai, MD, PhD, who was appointed NCI director by the Trump administration in September.
Letai did not cite new evidence that might have prompted the institute to research the effectiveness of the antiparasitic drug against cancer. The drug, largely used to treat people or animals for infections caused by parasites, is a popular dewormer for horses.
"We'll probably have those results in a few months," Letai said. "So we are taking it seriously."
He spoke about ivermectin at a Jan. 30 event, "Reclaiming Science: The People's NIH," with National Institutes of Health Director Jay Bhattacharya, MD, PhD, and other senior agency officials at Washington, D.C.'s Willard Hotel. The MAHA Institute hosted the discussion, framed by the "Make America Healthy Again" agenda of HHS Secretary Robert F. Kennedy Jr. The National Cancer Institute is the largest of the NIH's 27 branches....<<<Read More>>>...
